Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of IN-C005 vs IN-A001 (Tegoprazan) in Healthy Caucasian Subjects
NCT05005065Phase 1Completed
- Sponsor
- HK inno.N Corporation
- Start
- Sep 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of IN-C005 in gastroesophageal reflux disease (GERD) and Helicobacter pylori infection (4 arms), sponsored by HK inno.N Corporation. Primary endpoints: Maximum Plasma Concentration at Day 22, Area Under the Curve to Last Measurable Concentration at Day 22 and 4 more. Started Sep 2021; status: completed.
02
Drugs
IN-C005
03
Conditions
gastroesophageal reflux disease (GERD)Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05005065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05005065.